AbbVie (ABBV) Price to Sales (2012 - 2026)

AbbVie (ABBV) has reported Price to Sales for 15 consecutive years, with 26.17 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Sales rose 23.1% year-over-year to 26.17 in Q2 2026; TTM through Jun 2026 was 6.91, a 22.85% increase from a year earlier, with the FY2025 full-year figure at 6.61, up 18.62% from the prior year.
• Price to Sales was 26.17 for Q2 2026 at AbbVie, up from 25.61 in the prior quarter.
• Over five years, Price to Sales peaked at 27.74 in Q1 2025 and troughed at 16.02 in Q3 2022.
• A 5-year average of 21.99 and a median of 21.21 in 2022 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales jumped 44.03% in 2022 and declined 7.65% in 2026, its largest moves.
• Over 5 years, Price to Sales stood at 18.91 in 2022, then advanced by 1.22% to 19.14 in 2023, then gained by 8.52% to 20.77 in 2024, then grew by 17.04% to 24.31 in 2025, then rose by 7.66% to 26.17 in 2026.
• The last three Price to Sales figures came in at 26.17 (Q2 2026), 25.61 (Q1 2026), and 24.31 (Q4 2025), per Business Quant data.